To include your compound in the COVID-19 Resource Center, submit it here.

TG aims for accelerated approval of lymphoma candidate

TG Therapeutics Inc. (NASDAQ:TGTX) said umbralisib (TGR-1202) met the primary endpoint in a cohort of marginal zone lymphoma patients in a pivotal

Read the full 228 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE